<?xml version="1.0" encoding="UTF-8"?>
<p id="Par87">The study will assess adverse events (AE) and serious adverse events (SAE) using the criteria of the NCI CTCAE V4.0 [
 <xref ref-type="bibr" rid="CR21">21</xref>]. The known common AEs associated with THC/CBD will be specifically addressed at each time point. Finally, a detailed concurrent medication list is to be updated and recorded at baseline (day 0) and days 7, 14, 21 and 28. This is to include over-the-counter medications, prescribed medications and complementary medication.
</p>
